GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (FRA:IKAP) » Definitions » Institutional Ownership

Aurinia Pharmaceuticals (FRA:IKAP) Institutional Ownership : 16.78% (As of May. 14, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Aurinia Pharmaceuticals Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Aurinia Pharmaceuticals's institutional ownership is 16.78%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Aurinia Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Aurinia Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 100.77%.


Aurinia Pharmaceuticals Institutional Ownership Historical Data

The historical data trend for Aurinia Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurinia Pharmaceuticals Institutional Ownership Chart

Aurinia Pharmaceuticals Historical Data

The historical data trend for Aurinia Pharmaceuticals can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 15.75 15.46 15.71 15.94 16.32 16.37 16.95 16.94 16.83 16.78

Aurinia Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Aurinia Pharmaceuticals (FRA:IKAP) Business Description

Traded in Other Exchanges
Address
4464 Markham Street, Suite 1203, Victoria, BC, CAN, V8Z 7X8
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States.

Aurinia Pharmaceuticals (FRA:IKAP) Headlines

No Headlines